We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Gulsah
Cetinkaya
gulsah.cetinkaya1@nhs.net
tina
bruun
tina.bruun.01@regionh.dk
Ann
Sullivan
ann.sullivan2@nhs.net
Ann
Sullivan
ann.sullivan2@nhs.net
More information about this study, what is involved and how to take part can be found on the study website.
Human immunodeficiency virus [HIV] disease
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
Pre-exposure prophylaxis (PrEP) is when antiretroviral medication (medication usually taken to treat HIV infection) is taken by people not infected with HIV to prevent HIV acquisition. It has been shown to be highly efficacious, effective and cost-effective within specific population groups in Europe. However, people unknowingly infected with HIV can develop resistance to antiretroviral therapy if they start or continue to use PrEP after they are infected. The PrEPaRe study is an observational study collecting individual level data on people newly diagnosed with HIV and who report having used PrEP. The aim is to understand the circumstances under which these HIV infections occurred and to estimate the prevalence of HIV drug resistance in those people who have taken PrEP.
Aggregate data on the number of people newly diagnosed with HIV will also be collected in order to assess the use of PrEP among people newly diagnosed with HIV. Data will be collected from clinics across Europe (including the UK); the clinics involved will be those clinics where HIV is diagnosed and/or HIV care is delivered.
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
Observational type: Qualitative;
You can take part if:
You may not be able to take part if:
People are excluded if they do not meet all the eligibility criteria above.
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
Ann
Sullivan
ann.sullivan2@nhs.net
tina
bruun
tina.bruun.01@regionh.dk
Ann
Sullivan
ann.sullivan2@nhs.net
Gulsah
Cetinkaya
gulsah.cetinkaya1@nhs.net
More information about this study, what is involved and how to take part can be found on the study website.
The study is sponsored by CHIP (Centre of Excellence for Health, Immunity and Infections) Denmark and funded by Rigshospitalet (Denmark) .
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Read full details
for Trial ID: CPMS 44668
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
